

## Supplementary material

**Table S1. Univariate analysis of Liver Stiffness predictors.** ILD: interstitial lung disease; HCQ: hydroxychloroquine; MTX: methotrexate; BMI: body mass index; WC: waist circumference; AC: arm circumference; ANA: anti-nuclear antibodies; Anti-RNP: anti ribonucleoprotein antibodies; Anti-dsDNA: anti double strand DNA; AMA: anti-mitochondrial antibodies; Gp210: Anti-glycoprotein-210 antibodies; ALT: alanine-aminotransferase; AST: aspartate-aminotransferase; GGT: gamma-glutamyltransferase; ALP: alkaline phosphatase.

	<b>Odds Ratio</b>	<b><i>p</i></b>
<b>Male gender</b>	2.12 [0.49-9]	0.31
<b>Age</b>	2.89 [0.92-9.09]	0.07
<b>Disease duration</b>	0.62 [0.2-1.94]	0.40
<b>SSc variant</b>	3.13 [0.38-25.71]	0.29
<b>ILD</b>	1.48 [0.46-4.81]	0.51
<b>Gastrointestinal involvement</b>	1.47 [0.5-4.37]	0.49
<b>Arterial hypertension</b>	1.45 [0.49-4.28]	0.50
<b>Active cancer</b>	1.64 [0.4-6.77]	0.49
<b>Cardiac disease</b>	2.89 [0.84-9.93]	0.09
<b>Diabetes</b>	1.28 [0.13-12.3]	0.83
<b>Alcohol</b>	<b>4.17[1.02-16.97]</b>	<b>0.04</b>
<b>Smoke</b>	2.64 [0.83-8.4]	0.10
<b>HCQ</b>	1.05 [0.31-3.61]	0.94
<b>Steroids</b>	0.73 [0.23-2.7]	0.71
<b>MTX</b>	0.42 [0.05-3.54]	0.43
<b>BMI</b>	1.78 [0.59-5.34]	0.30
<b>WC</b>	<b>4.13 [1.3-13.06]</b>	<b>0.02</b>
<b>AC</b>	1.23 [0.13-11.99]	0.86
<b>ANA</b>	1.34 [0.27-6.6]	0.72

<b>Anti-Ro</b>	0.67 [0.14-3.30]	0.63
<b>Anti-Ro60</b>	1.01 [0.20-5.14]	0.99
<b>Anti-Ro52</b>	0.61 [0.07-5.23]	0.65
<b>Anti-La</b>	5.64 [0.73-43.43]	0.10
<b>Anti-RNP</b>	2.12 [0.49-9.0]	0.31
<b>Anti-dsDNA</b>	1.00 [0.11-9.18]	1.000
<b>AMA</b>	<b>4.67 [1.44-15.13]</b>	<b>0.01</b>
<b>Sp100</b>	0.5 [0.03-9.78]	0.65
<b>Gp210</b>	15 [0.58-385.62]	0.10
<b>ALT</b>	4.44 [0.89-22.18]	0.07
<b>AST</b>	3.72 [0.57-24.28]	0.17
<b>ALP</b>	<b>34.09 [3.64-319.71]</b>	<b>0.002</b>
<b>GGT</b>	2.87 [0.9-9.2]	0.08

**Table S2. Univariate analysis of Liver Steatosis predictors.** ILD: interstitial lung disease; HCQ: hydroxychloroquine; MTX: methotrexate; BMI: body mass index; WC: waist circumference; AC: arm circumference; ANA: anti-nuclear antibodies; Anti-RNP: anti ribonucleoprotein antibodies; Anti-dsDNA: anti double strand DNA; AMA: anti-mitochondrial antibodies; Gp210: Anti-glycoprotein-210 antibodies; ALT: alanine-aminotransferase; AST: aspartate-aminotransferase; GGT: gamma-glutamyltransferase; ALP: alkaline phosphatase.

	<b>Odds Ratio</b>	<b><i>p</i></b>
<b>Male gender</b>	1.90 [0.1-36.11]	0.668
<b>Age</b>	1.12 [0.21-5.85]	0.894
<b>Disease duration</b>	3.24 [0.56-18.3]	0.189
<b>SSc variant</b>	0.85 [0.09-7.92]	0.891
<b>ILD</b>	3.24 [0.61-17.26]	0.169
<b>Gastrointestinal involvement</b>	4.14 [0.72-23.92]	0.113
<b>Arterial hypertension</b>	2.24 [0.39-12.85]	0.366

Active cancer	1.28 [0.14-11.95]	0.827
Cardiac disease	0.99 [0.12-9.06]	0.991
Diabetes	<b>14.33 [1.84-111.45]</b>	<b>0.011</b>
Alcohol	0.58 [0.03-11.01]	0.713
Smoke	0.26 [0.01-4.83]	0.367
HCQ	1.85 [0.21-16.62]	0.585
Steroids	0.48 [0.05-4.35]	0.518
MTX	1.58 [0.17-14.92]	0.690
BMI	<b>11.7 [1.31-105.41]</b>	<b>0.028</b>
WC	<b>12.08 [1.34-108.96]</b>	<b>0.026</b>
AC	4.06 [0.36-45.36]	0.255
ANA	2.50 [0.13-46.80]	0.541
Anti-Ro	0.34 [0.02-6.30]	0.467
Anti-Ro60	0.48 [0.03-9.0]	0.621
Anti-Ro52	0.65 [0.03-12.5]	0.776
Anti-La	1.46 [0.07-30.21]	0.806
Anti-RNP	1.58 [0.17-14.92]	0.690
Anti-dsDNA	0.98 [0.05-19.32]	0.988
AMA	1.09 [0.11-10.46]	0.938
Sp100	5.53 [0.48-63.27]	0.169
Gp210	5.18 [0.19-142.58]	0.331
ALT	2.77 [0.28-27.63]	0.386
AST	4.25 [0.4-45.45]	0.231
ALP	0.93 [0.07-18.39]	0.961
GGT	0.79 [0.09-7.18]	0.833

**Table S3. Stepwise logistic regression for liver steatosis. For abbreviation: BMI: body mass index**

	$\beta$	Standard Error	p
BMI	0.216	0.173	0.214
Waist circumference	0.045	0.174	0.797

<b>Diabetes</b>	<b>0.264</b>	<b>0.103</b>	<b>0.012</b>
-----------------	--------------	--------------	--------------